Clinical trials: Nasopharyngeal Carcinoma (NPC)
Nutrition Disorders, Quality of Life
Early Use of Opioid in Radiation Mucositis
This study is a superiority research to evaluate the safety and effectiveness of early use of oxycodone control release tablet for radiation mucositis in nasopharyngeal carcinoma patients.
- Trial name
- NCT02309437
- Testing
- Oxycodone
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Head and Neck Cancer
Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003637
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- Singapore
- Volunteers
- 200 people
- Sponsor
- National Cancer Centre, Singapore
Locally Advanced Nasopharyngeal Carcinoma
Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
The purpose of this study was to investigate the role of immunonutrion compared with standard nutrition in reducing oral mucositis in patients with locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT05892354
- Testing
- Enteral immunonutrition, Standard enteral nutrition
- Where
- 20 sites in China
- Volunteers
- 190 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Cancinoma (NPC), SBRT
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
This study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (ORR), of SBRT combined with Nimotuzumab followed by…
- Conditions
- Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
- Trial name
- NCT06676722
- Testing
- SBRT combined with Nimotuzumab followed by Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Head and Neck Cancer, Lymphedema
Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer
RATIONALE: Developing a symptom checklist for late-effect lymphedema may help doctors learn more about lymphedema in patients with head and neck cancer and plan the best treatment.
- Trial name
- NCT00840814
- Where
- 3 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Nasopharyngeal Carcinoma
Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is a head and neck tumor. Studies have shown that more than 70% of patients are diagnosed with locally advanced nasopharyngeal carcinoma at the time of initial diagnosis.
- Trial name
- NCT05508347
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Nasopharyngeal Cancer, Epstein Barr Virus Infections
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
This clinical study is looking at a vaccine called MVA-EBNA1/LMP2. This is a new vaccine that has already been studied in small number of cancer patients.
- Trial name
- NCT01800071
- Testing
- MVA-EBNA1/LMP2 vaccine
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cancer Research UK
Nasopharyngeal Carcinoma
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
Hypothesis We hypothesise that intermittent dosing of the anti-angiogenic RTKI sunitinib or bevacizumab prior to systemic cisplatin and gemcitabine chemotherapy to transiently "normalise" tumour vasculature in patients with…
- Trial name
- NCT01309633
- Testing
- 12.5mg sunitinib with Cisplatin and Gemcitabine, 25mg Sunitinib alternating with Cisplatin and Gemcitabine, 7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- National University Hospital, Singapore
Solid Tumor, Small Cell and Non-small Cell Lung Cancer
RAPA-201 Therapy of Solid Tumors
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of…
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT05144698
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rapa Therapeutics LLC
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare the survival and toxicity of GP (gemcitabine and cisplatin) vs. PF (cisplatin and fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
- Trial name
- NCT03840421
- Testing
- gemcitabine and cisplatin, cisplatin and fluorouracil, IMRT
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis
The purpose of this study is to determine if the screening of nasopharyngeal carcinoma using plasma Epstein-Barr virus DNA analysis would result in the detecting NPC cases at earlier stages and improve survival.
- Trial name
- NCT02063399
- Where
- Hong Kong
- Volunteers
- 20,302 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Carcinoma of Unknown Primary, Head and Neck Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002507
- Testing
- mitomycin C, porfiromycin, brachytherapy
- Where
- United States
- Sponsor
- Yale University
Nasopharyngeal Neoplasms
Taxotere + Cisplatin in Nasopharyngeal Carcinoma
Primary objective: To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin.
- Trial name
- NCT00436293
- Testing
- Docetaxel, Cisplatin
- Where
- Hong Kong
- Volunteers
- 61 people
- Sponsor
- Sanofi
Head and Neck Cancer, Precancerous Condition
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00978081
- Testing
- aminolevulinic acid hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Nasopharyngeal Carcinoma
Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)
Study Objective: Primary 1. To evaluate the complete response (CR) rate with induction chemotherapy using Docetaxel, Cisplatin and Fluorouracil(TPF) followed by Docetaxel plus Cetuximab (TC) in concurrence with…
- Trial name
- NCT01326559
- Testing
- Docetaxel, Cisplatin, 5-FU and Cetuximab
- Where
- 4 sites in China
- Volunteers
- 33 people
- Sponsor
- Hong Kong Nasopharyngeal Cancer Study Group Limited
Recurrent Metastatic Nasopharyngeal Carcinoma
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment
This is a randomized, open-label, positive-controlled, multicenter Phase Ш study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with capecitabine versus capecitabine monotherapy in…
- Trial name
- NCT05717764
- Testing
- Mitoxantrone hydrochloride liposome injection, Capecitabine
- Volunteers
- 500 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Dysphagia
Functional Electrical Stimulation in Irradiated Nasopharyngeal Carcinoma (NPC)
The purpose of this study is to determine whether functional electrical stimulation is effective in the treatment of dysphagia due to nasopharyngeal cancer post radiotherapy
- Trial name
- NCT00815087
- Testing
- Functional electrical stimulation, Exercise home program
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Nasopharyngeal Carcinoma
Individualized Elective Neck Irradiation Based on MRI in NPC Patients
Currently, most protocols of nasopharyngeal carcinoma (NPC) of various research bodies such as the Radiation Therapy Oncology Group require routine elective irradiation to the retropharyngeal area and to levels II-V lymph nodal…
- Trial name
- NPC-CTVn (NCT02642107)
- Testing
- Elective neck irradiation, Whole neck irradiation
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Sun Yat-sen University
Metastatic Nasopharyngeal
A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma
1. To demonstrate the feasibility of leukapheresis and ex vivo activation of autologous NK cells in patients with metastatic NPC 2.
- Trial name
- NCT00717184
- Testing
- Interleukin, NK cells
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma, Head and Neck Cancer
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year.
- Conditions
- Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker
- Trial name
- NCT06307314
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Nanfang Hospital, Southern Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.